Zentalis Pharmaceuticals, Inc. - ZNTL

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Mar 03, 2026 SCHEDULE 13G Squadron Master Fund LP 5.1% 3,676,900 View
Mar 03, 2026 SCHEDULE 13G Squadron Capital Management LLC 5.1% 3,676,900 View
Mar 03, 2026 SCHEDULE 13G Matthew Sesterhenn 5.1% 3,676,900 View
Mar 03, 2026 SCHEDULE 13G William Blank 5.1% 3,676,900 View
Jan 05, 2026 SCHEDULE 13G/A Walters William T 19.7% 13,509,973 View
Jan 05, 2026 SCHEDULE 13G/A WALTERS GROUP 19.7% 13,509,973 View
Jan 05, 2026 SCHEDULE 13G/A Walters, Susan B. 19.7% 13,509,973 View
Jan 02, 2026 SCHEDULE 13D/A View
Dec 30, 2025 SCHEDULE 13G 5AM Opportunities II (GP), LLC 5.2% 3,947,913 View
Dec 30, 2025 SCHEDULE 13G 5AM Opportunities II, L.P. 5.2% 3,947,913 View
Dec 30, 2025 SCHEDULE 13G 5AM Opportunities (GP), LLC 1.2% 890,658 View
Dec 30, 2025 SCHEDULE 13G 5AM Opportunities Master Fund L.P. 1.2% 890,658 View
Dec 30, 2025 SCHEDULE 13G Andrew J. Schwab 6.4% 4,838,571 View
Dec 30, 2025 SCHEDULE 13G Kush Parmar 6.4% 4,838,571 View
Dec 30, 2025 SCHEDULE 13G Anna Yaeger 1.2% 890,658 View
Dec 15, 2025 SCHEDULE 13D/A View
Nov 12, 2025 SCHEDULE 13G Barclays PLC 5.32% 3,841,449 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.